CDTX insider sell-to-cover: 474 shares sold to satisfy RSU taxes
Rhea-AI Filing Summary
Cidara Therapeutics insider sale to cover RSU taxes Nicole Davarpanah, the company's Chief Medical Officer, sold 474 shares of Cidara Therapeutics common stock on 09/11/2025 to satisfy tax withholding obligations tied to vested restricted stock units. The weighted-average sale price reported is $62.8627, with transaction prices ranging from $62.86 to $63.50. After the reported sale, the reporting person beneficially owns 31,418 shares; this total includes 200 shares purchased through the company Employee Stock Purchase Plan on May 20, 2025. The Form 4 was executed by an attorney-in-fact on 09/15/2025.
Positive
- Full disclosure of a sell-to-cover transaction and price range, showing compliance with reporting rules
- Substantial retained ownership: reporting person still beneficially owns 31,418 shares after the transaction
Negative
- Insider sold shares (474) — although described as sell-to-cover, sales can be viewed negatively by some investors
- Limited detail on exact share-level executions within the price range; reporting person offers to provide details on request
Insights
TL;DR: Routine sell-to-cover for RSU tax withholding; small transaction relative to total holdings, limited market impact.
The Form 4 shows a disposition of 474 shares via a sell-to-cover tied to RSU settlement rather than an open-market discretionary sale. The weighted-average price is $62.8627, with a narrow reported price range, suggesting routine execution. The reporting person retains 31,418 shares post-transaction, which indicates continued significant ownership. From a financial perspective, this filing is a standard insider tax-withholding action and unlikely to materially affect CDTX's valuation.
TL;DR: Proper disclosure of an RSU-related sell-to-cover; demonstrates compliance with Section 16 reporting obligations.
The filing clearly states the sale was to cover tax withholding for vested RSUs and includes an explanation of the weighted-average price range and inclusion of ESPP shares. The signature by an attorney-in-fact is present and the form identifies the reporting person as an officer (Chief Medical Officer). This is a routine, compliant disclosure without indications of unusual timing or governance concerns.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 474 | $62.8627 | $30K |
Footnotes (1)
- The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.86 to $63.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2025.
